Journal
BIOMOLECULES
Volume 11, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/biom11111648
Keywords
immunotherapy; resistance; miRNA; biomarker
Categories
Funding
- MOST [110-2628-B-001, 110-2823-B-008-002]
Ask authors/readers for more resources
Immune checkpoint inhibitors show promise in cancer treatment, but resistance in melanoma patients hinders their effectiveness. Recent studies explore the role of miRNAs in immune response and tumor microenvironment, suggesting their potential as key players in immunotherapy.
Immune checkpoint inhibitors are a promising therapy for the treatment of cancers, including melanoma, that improved benefit clinical outcomes. However, a subset of melanoma patients do not respond or acquire resistance to immunotherapy, which limits their clinical applicability. Recent studies have explored the reasons related to the resistance of melanoma to immune checkpoint inhibitors. Of note, miRNAs are the regulators of not only cancer progression but also of the response between cancer cells and immune cells. Investigation of miRNA functions within the tumor microenvironment have suggested that miRNAs could be considered as key partners in immunotherapy. Here, we reviewed the known mechanism by which melanoma induces resistance to immunotherapy and the role of miRNAs in immune responses and the microenvironment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available